Research output per year
Research output per year
Fingerprint
Dive into the research topics where Raushan T Kurmasheva is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A very long-acting PARP inhibitor suppresses cancer cell growth in DNA repair-deficient tumor models
Fontaine, S. D., Ashley, G. W., Houghton, P. J., Kurmasheva, R. T., Diolaiti, M., Ashworth, A., Peer, C. J., Nguyen, R., Figg, W. D., Beckford-Vera, D. R. & Santi, D. V., Feb 15 2021, In: Cancer Research. 81, 4, p. 1076-1086 11 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium
Kurmasheva, R. T., Erickson, S. W., Earley, E., Smith, M. A. & Houghton, P. J., Feb 2021, In: Pediatric Blood and Cancer. 68, 2, e28772.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
PCAT: An integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models
Yang, J., Li, Q., Noureen, N., Fang, Y., Kurmasheva, R., Houghton, P. J., Wang, X. & Zheng, S., Jan 8 2021, In: Nucleic acids research. 49, D1, p. D1321-D1327Research output: Contribution to journal › Article › peer-review
Open Access -
The B7-H3–targeting antibody–Drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models
Kendsersky, N. M., Lindsay, J., Anders Kolb, E., Smith, M. A., Teicher, B. A., Erickson, S. W., Earley, E. J., Mosse, Y. P., Martinez, D., Pogoriler, J., Krytska, K., Patel, K., Groff, D., Tsang, M., Ghilu, S., Wang, Y., Seaman, S., Feng, Y., St Croix, B., Gorlick, R. & 3 others, , May 2021, In: Clinical Cancer Research. 27, 10, p. 2938-2946 9 p.Research output: Contribution to journal › Article › peer-review
-
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium
Gill, J., Zhang, W., Zhang, Z., Roth, M., Harrison, D. J., Rowshan, S., Erickson, S., Gatto, G., Kurmasheva, R., Houghton, P., Teicher, B., Smith, M. A., Kolb, E. A. & Gorlick, R., Oct 1 2020, In: Pediatric Blood and Cancer. 67, 10, e28606.Research output: Contribution to journal › Article › peer-review
4 Scopus citations